N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide
C21H19BrF3N3OS — CID 158146815
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide
N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide (PubChem CID 158146815) has the molecular formula C21H19BrF3N3OS and a molecular weight of 498.37 g/mol. Its IUPAC name is N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide.
Molecular Properties
| Compound Name | N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide |
|---|---|
| PubChem CID | 158146815 |
| Molecular Formula | C21H19BrF3N3OS |
| Molecular Weight | 498.37 g/mol |
| Exact Mass | 497.04 |
| IUPAC Name | N-[1-[5-[3-bromo-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]-2-(4-ethylphenyl)ethyl]acetamide |
| SMILES | CCc1ccc(CC(NC(C)=O)c2nnc(-c3cc(Br)cc(C(F)(F)F)c3)s2)cc1 |
| InChI | InChI=1S/C21H19BrF3N3OS/c1-3-13-4-6-14(7-5-13)8-18(26-12(2)29)20-28-27-19(30-20)15-9-16(21(23,24)25)11-17(22)10-15/h4-7,9-11,18H,3,8H2,1-2H3,(H,26,29) |
| InChIKey | PTSAUJOHVTZDKY-UHFFFAOYSA-N |
| XLogP | 5.97 |
| TPSA | 54.88 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 498.37 |
| LogP ≤ 5 | 5.97 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158146815 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.